O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy; D003131:Combined Modality Therapy; D060830:Consolidation Chemotherapy; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D018572:Disease-Free Survival; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D004941:Esophagitis / Q000209:etiology; D018773:Genes, erbB-1; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy; D017239:Paclitaxel / Q000008:administration & dosage; D011446:Prospective Studies; D011799:Quinazolines / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000209:etiology; D017564:Radiation Pneumonitis / Q000209:etiology; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage
D004273:DNA, Neoplasm; D011799:Quinazolines; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D000069347:Erlotinib Hydrochloride; D017239:Paclitaxel